文献速递细菌感染、耐药与抗菌药物医院感染防控

改进革兰阴性菌血症经验性抗生素选择的决策(IDEAS):一项前瞻性临床实施研究

Improving Decision Making in Empiric Antibiotic Selection (IDEAS) for Gram-negative Bacteremia: A Prospective Clinical Implementation Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在大型学术三级医疗机构开展准实验设计,比较干预前后各9个月革兰阴性菌血症患者。干预由抗菌药物管理药师基于个体化耐药预测模型提供经验性治疗建议。结果显示干预组降阶梯治疗比例更高(29% vs 21%;aOR=1.77;95%CI 1.09-2.87;P=.02),培养最终报告时使用最窄充分治疗的比例更高(55% vs 44%;aOR=2.04;95%CI 1.27-3.27;P=.003),而充分治疗时间无差异(5 vs 4小时;P=.95)。

要点

  • 基于个体化耐药预测模型的AMS干预可促进革兰阴性菌血症经验性抗生素早期降阶梯。
  • 干预提高了培养最终报告时使用最窄充分治疗的患者比例(55% vs 44%)。
  • 干预未延长充分治疗时间(5 vs 4小时;P=.95)。

核心结论

  • 基于个体化耐药预测模型的抗菌药物管理干预可影响革兰阴性菌血症经验性抗生素选择,促进早期降阶梯治疗而不损害覆盖充分性。

研究设计与样本

  • 准实验设计,比较干预前后两个9个月期间在大型学术三级医疗机构革兰阴性菌血症发作情况。
  • 干预前期间纳入182例次菌血症发作,干预后期间纳入201例次。
  • 使用多变量模型预测血流感染革兰阴性菌对头孢曲松、环丙沙星、头孢他啶、哌拉西林-他唑巴坦和美罗培南的敏感性概率,并结合现有耐药预测方法生成个体化经验性治疗建议,由抗菌药物管理药师提供给处方者。

主要发现

  • 干预组降阶梯治疗比例高于对照组(29% vs 21%;aOR=1.77;95%CI 1.09-2.87;P=.02)。
  • 干预组在培养最终报告时使用最窄充分治疗的比例高于对照组(55% vs 44%;aOR=2.04;95%CI 1.27-3.27;P=.003)。
  • 干预组与对照组充分治疗时间相似(5 vs 4小时;P=.95)。

临床怎么用

  • 临床可借助基于个体化耐药预测模型的抗菌药物管理药师干预,优化革兰阴性菌血症经验性抗生素选择并促进早期降阶梯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Timely selection of adequate empiric antibiotics has become increasingly difficult due to rising resistance rates and the competing desire to apply antimicrobial stewardship (AMS) principles. Individualized clinical prediction models offer the promise of reducing broad-spectrum antibiotic use and preserving/improving adequacy of treatment, but few have been validated in the clinical setting. METHODS: Multivariable models were used to predict the probability of susceptibility for gram-negative (GN) bacteria in bloodstream infections (bacteremia) to ceftriaxone, ciprofloxacin, ceftazidime, piperacillin-tazobactam, and meropenem. The models were combined with existing resistance-prediction methods to generate optimized and individualized suggestions for empiric therapy that were provided to prescribers by an AMS pharmacist. De-escalation of empiric antibiotics and adequacy of therapy were analyzed using a quasi-experimental design comparing two 9-month periods (pre- and postintervention) at a large academic tertiary care institution. RESULTS: Episodes of bacteremia (n = 182) were identified in the preintervention and postintervention (n = 201) periods. Patients who received the intervention were more likely to have their therapy de-escalated (29 vs 21%; aOR = 1.77; 95% CI, 1.09-2.87; P = .02). The intervention also increased the proportion of patients who were on the narrowest adequate therapy at the time of culture finalization (44% in the control and 55% in the intervention group; aOR = 2.04; 95% CI, 1.27-3.27; P = .003). Time to adequate therapy was similar in the intervention and control groups (5 vs 4 hours; P = .95). CONCLUSIONS: An AMS intervention, based on individualized predictive models for resistance, can influence empiric antibiotic selections for GN bacteremia to facilitate early de-escalation of therapy without compromising adequacy of antibiotic coverage.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Elligsen M, Pinto R, Leis JA, et al. Improving Decision Making in Empiric Antibiotic Selection (IDEAS) for Gram-negative Bacteremia: A Prospective Clinical Implementation Study. Clin Infect Dis. 2021. PMID: 32640028. doi:10.1093/cid/ciaa921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。